Eddie is mainly responsible for the deal sourcing, due diligence and operations in Rimonci, and he is also highly involved in the post investment management process to help the portfolio companies to develop in China. Prior to Rimonci, Eddie has already been working in investment industry for years. His personal career started from the financial investment area, where he was focused on the investment as well as fundraising in one of the top private equity investment company in China. After that, Eddie switched to strategic investment and worked as the general manager of the group strategic investment department in one of the Chinese comprehensive IT group, mainly in charge of the group investment, M&A and overseas business development. Eddie has both the B.S in Economics and MBA degrees from Tsinghua University, and also MBA from Hebrew University. He is fluent in English and has rich oversea life experience. During the college, Eddie used to study and work in Korea, India, Uganda, Kenya, and Dubai for years, which helped him to build up the skills for cross culture communications.
Richel is Founder and CEO of Rimonci Capital，the member of the fund investment committee. She is responsible for Rimonci overall strategies and transactions control. Prior to founding Rimonci at start of 2016, Richel served as CEO of a comprehensive IT group in China with 1.5 billion USD in sales, and also Executive Director of HK listed company and chairman of Shanghai listed company in this group. During her tenure, Richel was responsible for different business investment and operation, especially electronics, IC substrate, enterprise software, system integration and finally the overall management of the whole group. With more than 17 years of investment, mergers and acquisitions, business operation and management experience, she has distinguished tracking record on setting up new business and grow business from earlier stage to mature stage either by organic growth or through investment. Richel also have abundant cross-board working experience, competent for multiple board governance structure and management. Richel earned MS degree in economics and BS degree in engineering, also Received Senior Leadership Training Certification from Yale School of Management. Acquired the certification of Eye, Ear, Nose & Throat Innovation by Biodesign of Stanford and Byers Eye Institute. With the qualifications for securities and funds in China. Be the member of Singapore National Eye Center Ophthalmic Technologies Incubator Venture Capital advisory panel.
Rina is partner & BD VP of Rimonci, she is responsible for BD development, post- investment management and public relationships. Prior to joining Rimonci, she used to work for the Embassy of Israel as senior trade officer for 6 years. She helped Israeli companies in the investment，ICT and homeland security industry to develop their businesses in China, and also helped distinguished Chinese companies find innovative technology and M&A opportunities in Israel. She did great bridge job for government officials, entrepreneurs and senior executives both from China and Israel. Before working for embassy, she worked for Alcatel-Lucent and Intel in business development for more than 10 years. Rina is passionate, responsible and considerate. She has an MBA from Cardiff University，United Kingdom. Rina is very fluent at English and having the qualifications for securities and funds in China.
Wei Wei, CPA, CTA and senior florist, is in charge of finance and compliance management in Rimonci. Wei has accumulated rich experience in strategic advisory and corporate finance during her service as assistant manager in KPMG, senior strategy manager and executive assistant to CEO of a multi-billion-dollar-asset company, and financial director in a comprehensive finance group. Wei has an MBA from IESE Business School and double-bachelor in Financial Management and English from Tianjin University. She has advanced professional proficiency in English, and business proficiency in Spanish and Korean.
David is responsible for scouting deals, conducting due diligence, and assisting in all the work related to Aier Rimonci Accelerator. Prior to joining Rimonci Capital, David worked on eye movement research at NYU Langone Medical Center, and developed an automatic software for the quantitatively analysis of eye movements. David also worked at an international hedge fund, where he applied signal processing techniques to implement clustering, and design trading strategies. David received B.E. degree in Mechanical Engineering and Automation from Shanghai University, and PhD degree in Electrical Engineering from New York University, his expertise includes digital signal processing, machine learning, eye movement analysis, and quantitative trading.
Mengtian Kang, MD & PhD, is mainly responsible for clinical assessment in Rimonci and serves as an ophthalmologist in Beijing Tongren Hospital, Capital Medical University. Her research mainly focuses on refractive error and anterior ocular diseases. She published over 40 papers, among which 7 were published with her as the first author. She has more than 8 years of experience in clinical trial management, epidemiology study and RCT design.She was recognized as “Young Elite Scientists Sponsorship Program” of China Association for Science and Technology(CAST) in 2019 and was awarded The first prize of Science Technology Improvement Award for“Myopia prevention and technology” project, and Science Research Achievement Award in Colleges and Universities, China(2019).
Prof. Belkin received an M.A. degree in Science from Cambridge University, England, and an M.D. degree in Medicine from the Hebrew University of Jerusalem, Israel. He is the author of over 250 scientific publications and holds over 25 patents. Prof Belkin established and was the first full-time director of the Tel Aviv University Eye Research Institute. He was also the head of the pediatric ophthalmology services at Hadassah University Hospital and Sheba Medical Center; Chairman of the Tel Aviv University Department of Ophthalmology and co-founder &President of the Israel Society of Eye and Vision Research.
Dr. SUN served in Eye & ENT hospital since 1984 and focus on glaucoma clinical and research. He is the Chairman of the Dept. of Ophthalmology&Vision Science of Shanghai Medical College, Fudan University. Also as the Chairman of Ophthalmology&Vision Science Committee of Chinese Research Hospital Association, President-elect of Chinese Ophthalmology Society, Vice Chairman of Chinese Glaucoma Society of Chinese Ophthalmology Society, and Vice President of Eye-Doctor Association of China. Dr. SUN holds eight scientific projects from China national or ministerial research funding in the last 5 years.
Gerald M. Ostrov
Mr. Ostrov has over 30 years of highly successful medical experience, especially in the field of optometry. Served as the global CEO and Chairman of Bausch+Lomb group, the global chairman of Johnson & Johnson visual health group, and the head of the pharmaceutical business of Ciba-Geigy Corp, Also, He is an active angel investor, actively investing in and helping various optometric start-ups in the United States, Israel and other countries. He received an undergraduate degree from Cornell University and an MBA from Harvard University.
Professor and Chairman of The Department of Ophthalmology, Ruprecht-Karls University of Heidelberg, Director of the IVCRC and The David J Apple International Laboratory of Ocular Pathology at The University-Eye Clinic of Heidelberg, Germany. In addition to clinical and academic aspects, Dr. Gerd is also very active in the ophthalmic industry. In Ophthalmologist Power List 2018, Top 100 most influential people in the world of ophthalmology, Dr. Gerd ranks second in the world, which is also the highest ranking of European ophthalmologists.
Cynthia, MD & PhD, associate professor, mainly responsible for Rimonci medical affairs. Cynthia has more than 15 years of experience in ophthalmic medical devices (MD) and medications research, including molecular biology, animal model experiments and clinical trials. She is familiar with the R&D, registration inspection, pre-clinical evaluation, clinical trials design and analysis of ophthalmic Class III MD. Cynthia graduated from Zhongshan Ophthalmic Center of Sun Yat-sen University and participated a joint supervision scheme at McGill University during PhD training. She used to work at Peking University People’s Hospital, and a MedTech startup specialized in active implantable medical devices and medical artificial intelligence. Cynthia has published more than 80 peer-review articles in academic journals (40+ published as first or corresponding authors), including Cell Death DIS, J Biol Chem, J Pharmaceutical Exp Ther, IOVS, Retina, BJO, Mediators Inflamm, etc. She has been recognized as High Caliber Personnel in Guangdong Province and Shenzhen, and the Beijing Nova Star in Science and Technology.